BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30176117)

  • 1. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.
    Walter D; Ferstl P; Waidmann O; Trojan J; Hartmann S; Schnitzbauer AA; Zeuzem S; Kraywinkel K
    Liver Int; 2019 Feb; 39(2):316-323. PubMed ID: 30176117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiocarcinoma miscoding in hepatobiliary centres.
    Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic classification of cholangiocarcinoma: New concepts.
    Nakanuma Y; Kakuda Y
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.
    Javle M; Lee S; Azad NS; Borad MJ; Kate Kelley R; Sivaraman S; Teschemaker A; Chopra I; Janjan N; Parasuraman S; Bekaii-Saab TS
    Oncologist; 2022 Oct; 27(10):874-883. PubMed ID: 35972334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
    Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
    J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
    Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
    Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma: A large population-based study.
    Liao P; Cao L; Chen H; Pang SZ
    Medicine (Baltimore); 2021 Apr; 100(16):e25635. PubMed ID: 33879742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New epidemiologic trends in cholangiocarcinoma.
    Pascale A; Rosmorduc O; Duclos-Vallée JC
    Clin Res Hepatol Gastroenterol; 2023 Nov; 47(9):102223. PubMed ID: 37797807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholangiocarcinoma: Epidemiology and risk factors.
    Khan SA; Tavolari S; Brandi G
    Liver Int; 2019 May; 39 Suppl 1():19-31. PubMed ID: 30851228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification.
    Tawarungruang C; Khuntikeo N; Chamadol N; Laopaiboon V; Thuanman J; Thinkhamrop K; Kelly M; Thinkhamrop B
    BMC Cancer; 2021 May; 21(1):497. PubMed ID: 33941120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.
    Wongjarupong N; Assavapongpaiboon B; Susantitaphong P; Cheungpasitporn W; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
    BMC Gastroenterol; 2017 Dec; 17(1):149. PubMed ID: 29216833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
    Bertuccio P; Malvezzi M; Carioli G; Hashim D; Boffetta P; El-Serag HB; La Vecchia C; Negri E
    J Hepatol; 2019 Jul; 71(1):104-114. PubMed ID: 30910538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.
    Schramm C; Sapuk A; Hoyer D; Radünz S; Schmidt H
    Z Gastroenterol; 2024 Jan; 62(1):37-42. PubMed ID: 38195106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of cholangiocarcinoma.
    Qurashi M; Vithayathil M; Khan SA
    Eur J Surg Oncol; 2023 Sep; ():107064. PubMed ID: 37709624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Targeted Therapies for Advanced Cholangiocarcinoma.
    Rizzo A; Brandi G
    Medicina (Kaunas); 2021 Feb; 57(3):. PubMed ID: 33652960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholangiocarcinoma Prognosis Varies over Time Depending on Tumor Site and Pathology.
    Kaneko R; Sato Y; Kobayashi Y
    J Gastrointestin Liver Dis; 2018 Mar; 27(1):59-66. PubMed ID: 29557416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pathways of genetic transformation in cholangiocarcinogenesis.
    Serafini FM; Radvinsky D
    Cancer Genet; 2016 Dec; 209(12):554-558. PubMed ID: 27720541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reality of cholangiocarcinoma in India- real world data from a tertiary referral centre.
    Patkar S; Gupta V; Khobragade K; Goel M
    HPB (Oxford); 2022 Sep; 24(9):1511-1518. PubMed ID: 35379594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical treatment of cholangiocarcinoma: an updated comprehensive review.
    Elvevi A; Laffusa A; Scaravaglio M; Rossi RE; Longarini R; Stagno AM; Cristoferi L; Ciaccio A; Cortinovis DL; Invernizzi P; Massironi S
    Ann Hepatol; 2022; 27(5):100737. PubMed ID: 35809836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression.
    Wang Y; Li K; Zhao W; Liu Z; Liu J; Shi A; Chen T; Mu W; Xu Y; Pan C; Zhang Z
    Cell Death Dis; 2021 Dec; 12(12):1158. PubMed ID: 34907179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.